Researchers Achieve Cancer-Killing Effect With Oral-Dose Vitamin C

[Guest guest]

Researchers Achieve Cancer-Killing Effect With Oral-Dose Vitamin C

_http://www.lewrockwell.com/sardi/sardi144.html_

(http://www.lewrockwell.com/sardi/sardi144.html)

by Bill Sardi

 

 

In an overlooked study first published in 2008, for the first time, using

a special liposomal form of oral-dose vitamin C, researchers in Britain

demonstrated it is possible to achieve cancer-killing blood concentrations of

this vitamin without undesirable side effects.

 

 

Heretofore, National Institutes of Health Researchers claimed the maximal

concentration of vitamin C that can be achieved following oral intake is

not sufficient to produce a cancer-killing effect. Now British researchers

demonstrate they were able to achieve blood concentrations of vitamin C that

were twice what was incorrectly reported to be maximal, and in the range of

what is known to be selectively toxic to tumor cells, yet not harmful to

healthy cells.

 

 

Studies with various forms of cancer show a 30%-to-50% cancer cell-killing

effect at the same blood concentration of vitamin C achieved in this

study. For comparison, anti-cancer drugs are approved by the FDA if they

achieve

50% tumor shrinkage.

 

 

Researchers Stephen Hickey and Hilary J. Roberts, long-time advocates of

vitamin C therapy and authors of the book _Ascorbate: The Science of Vitamin

C_

(http://www.amazon.com/gp/product/1411607244?ie=UTF8 & tag=lewrockwell & linkCode=xm\

2 & camp=1789 & creativeASIN=1411607244) , writing in the _Journal of

Nutritional & Environmental Medicine_

(http://informahealthcare.com/doi/abs/10.1080/13590840802305423) , believe even

higher concentration of vitamin C

can be achieved, up to three times what was once _mistakenly believed to be

maximal_ (http://www.ncbi.nlm.nih.gov/pubmed/15068981) , with measured,

repeated oral doses. .

 

 

It was Linus Pauling, the two-time Nobel Prize winner, who first _employed

intravenous vitamin C to prolong the lives of terminal cancer patients_

(http://www.ncbi.nlm.nih.gov/pubmed/279931) . This was reported in 1978..

 

 

A year later Mayo Clinic researchers then followed with a study of their

own, which utilized oral-dose vitamin C, and errantly _dispelled the notion

of using vitamin C to treat cancer_

(http://www.ncbi.nlm.nih.gov/pubmed/384241) . However, oral doses cannot

achieve the same high blood concentration

that intravenous vitamin C can produce.

 

 

Only recently has it come to light that the dismissal of vitamin C for

cancer therapy was based upon oral-dose vitamin C, and subsequent studies

found _intravenous vitamin C has the potential to be used in cancer therapy_

(http://www.ncbi.nlm.nih.gov/pubmed/18450228) . Some small _pilot studies_

(http://www.ncbi.nlm.nih.gov/pubmed/16567755) appear to be encouraging with

the use of intravenous vitamin C therapy. Cancer researchers have recently

called for a _reconsideration of intravenous vitamin C therapy_

(http://www.ncbi.nlm.nih.gov/pubmed/10963459) .

 

 

According to researchers Hickey and Roberts, repeated doses, and use of a

special _liposomal form of vitamin C_

(http://www.ncbi.nlm.nih.gov/pubmed/10368658) that is absorbed in the gut and

then into the liver before it is

released into the blood stream, are key to making oral vitamin C therapy

effective. Another important factor is to _limit the consumption of

carbohydrates_ (http://www.ncbi.nlm.nih.gov/pubmed/15695475) (refined sugar)

which

impairs oral absorption of this vitamin.

 

 

Dr. John Ely, emeritus professor at the University of Washington, has also

shown that _sugar depletes vitamin C from white blood cells_

(http://www.ncbi.nlm.nih.gov/pubmed/4074351) and makes them sluggish. White

blood cells

are the very cells that attack tumor cells and destroy them.

 

 

The liposomal form of vitamin C employed in this study consists of 1-gram

(1000 milligram) dose sachets of vitamin C powder encapsulated in lecithin

(phosphatidylcholine), as supplied by _Livon Laboratories_

(http://www.livonlabs.com/) of Henderson, Nevada, USA.

 

 

A British laboratory (Biolab, London) that has conducted thousands of

vitamin C assays over a 10-year period, confirms that 20-gram and 36-gram doses

of oral vitamin C, as utilized by researchers Hickey and Roberts, achieved

far higher blood concentration than had ever been measured previously.

Repeated dosing rather than massive single-dose vitamin C averts side effects

such as diarrhea.

 

 

The cancer cell-killing effect of vitamin C is realized by the transient

production of _hydrogen peroxide (H2O2) within connective tissues_

(http://www.ncbi.nlm.nih.gov/pubmed/18678913) (not in blood), which then

_destroys

tumor cells_ (http://www.ncbi.nlm.nih.gov/pubmed/19254759) , and

subsequently turns to harmless water (H2O), ensuring non-toxic therapy.

 

 

Reluctance by modern medical practitioners to offer vitamin C therapy to

their cancer patients suggests the public will have to practice vitamin C

therapy at home. This need not be a totally unguided experience, as there are

_instructive books_

(http://www.amazon.com/Vitamin-Remarkable-Controversial-Healing-Factor/dp/159120\

223X/ref=sr_1_1?ie=UTF8 & s=books & qid=1263386097 & sr=

1-1) available.

 

 

Why this landmark study has been completely overlooked by the cancer

community goes unexplained. The study was published in a journal catalogued by

the National Library of Medicine (NLM), but articles from that journal

cannot be accessed at the NLM website. When this report was submitted for

publication, the publisher of the journal suddenly changed editors and the new

editor attempted to scratch the report from its publication schedule

altogether. Finally the report did get published, but suddenly the journal

itself

was discontinued and its articles no longer indexed by NLM. It appears an

intentional effort was made to bury this study. An online abstract is provided

at the _Journal of Nutritional and Environmental Medicine_

(http://informahealthcare.com/doi/abs/10.1080/13590840802305423) website.

 

 

Pharmacokinetics of oral vitamin C

 

 

Stephen Hickey1,2†, Hilary J. Roberts3 and Nicholas J. Miller4

 

1. Faculty of Computing, Engineering and Technology, Staffordshire

University, Staffordshire, UK

 

2. School of Biology, Chemistry and Health Science, Manchester

Metropolitan University, Manchester, UK

 

3. Freelance scientific writer

 

4. Biolab Medical Unit, London, UK

 

 

†Correspondence: Stephen Hickey, Faculty of Computing, Engineering and

Technology, Staffordshire University, Staffordshire ST18 0DG, UK, 01785 353568

_s.hickey_ (s.hickey)

 

 

Purpose. To test whether plasma vitamin C levels, following oral doses in

supplemented volunteers, are tightly controlled and subject to a maximum in

the region of 220 µm L–1, as suggested by previous researchers for

depleted subjects. To determine plasma levels following single, variable-sized

doses of standard and liposomal formulations of vitamin C and compare the

effects of the different formulations. To determine whether plasma levels above

280 µm L–1, which have selectively killed cancer, bacteria or viruses (in

laboratory experiments), can be achieved using oral doses of vitamin C.

 

 

Design. This was a single blind study, measuring plasma levels in two

subjects, in samples taken half-hourly or hourly for 6 hours, following

ingestion of vitamin C. Data were compared with published results and with data

from 10 years of laboratory plasma determinations.

 

 

Materials and methods. Standard 1-gram tablets of vitamin C; liposomal

vitamin C. Plasma levels were analysed using the method of Butts and Mulvihill

..

 

 

Results. Preliminary investigations of the effects of liposomal and

standard formulation ascorbate showed that blood plasma levels in excess of the

previously assumed maximum of 220 µm L–1 are possible. Large oral doses of

liposomal ascorbate resulted in plasma levels above 400 µm L–1.

 

 

Conclusions. Since a single oral dose can produce plasma levels in excess

of 400 µm L–1, pharmacokinetic theory suggests that repeated doses could

sustain levels well above the formerly assumed maximum. These results have

implications for the use of ascorbate, as a nutrient and as a drug. For

example, a short in vitro treatment of human Burkitt's lymphoma cells with

ascorbate, at 400 µm L–1, has been shown to result in 50% cancer cell death.

Using frequent oral doses, an equivalent plasma level could be sustained

indefinitely. Thus, oral vitamin C has potential for use as a non-toxic,

sustainable, therapeutic agent. Further research into the experimental and

therapeutic aspects of high, frequent, oral doses of ascorbic acid either alone

or

(for cancer therapy) in combination with synergistic substances, such as

alpha-lipoic acid, copper or vitamin K3, is needed urgently.

 

 

January 15, 2010

 

 

Bill Sardi [_send him mail_ (BSardi) ] is a frequent

writer on health and political topics. His health writings can be found at

_www.naturalhealthlibrarian.com_ (http://www.naturalhealthlibrarian.com) . He is

the author of _You Don’t Have To Be Afraid Of Cancer Anymore_

(http://www.1shoppingcart.com/app/aftrack.asp?afid=662456) .